Ruxolitinib.
Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff...
https://pubmed.ncbi.nlm.nih.gov/24756798/Actively Recruiting
Led by Baptist Health South Florida · Updated on 2026-10-02
190
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of the investigational drug ruxolitinib when added to the standard treatment of radiation therapy and temozolomide for adults with newly diagnosed glioblastoma. This randomized phase 2 trial compares two groups one receiving ruxolitinib plus radiation and temozolomide, and the other receiving radiation and temozolomide alone. Participants are assigned to groups by chance to fairly assess the effects of adding ruxolitinib. The study includes two phases of drug administration during radiation therapy and a maintenance phase after radiation ends. Ruxolitinib is taken orally twice daily during radiation for six weeks, followed by a 4-week break, then continued in 28-day cycles until disease progression or intolerance. Temozolomide is also taken orally daily during radiation, then in cycles during maintenance. Radiation therapy is given every weekday for six weeks. Dose adjustments may occur if side effects develop. Participants will be monitored throughout the study with assessments including overall survival at four years as the primary outcome. Additional measures include survival rates at earlier times, progression-free survival, response rates, adverse events, mortality, and lab abnormalities. The study lasts up to four years, with regular follow-ups to evaluate treatment effects and safety.
CONDITIONS
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
M
Manmeet Ahluwalia, M.D., MBA
W
WCI Multisite Research Program
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Baptist Health South Florida
Lead Sponsor
Incyte Corporation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ruxolitinib plus radiation and temozolomide | Radiation and temozolomide | Current standard‑of‑care for newly diagnosed glioblastoma |
|---|---|---|---|
| What it is | An investigational regimen combining oral ruxolitinib with standard radiation and temozolomide in newly diagnosed glioblastoma. | Concurrent radiation therapy and temozolomide as used in the comparator arm in the clinical trial. | Maximal safe surgical resection followed by concurrent radiation and temozolomide, often with Tumor Treating Fields as part of standard care. |
| Role in the trial | Experimental arm testing whether adding ruxolitinib improves outcomes. | Control arm receiving standard radiation and temozolomide alone. | Represents current clinical practice outside of the trial setting. |
| Primary use | To evaluate whether adding ruxolitinib to standard radiotherapy and chemotherapy improves overall survival. | To serve as the standard concurrent treatment used in newly diagnosed glioblastoma within the trial. | To provide the established treatment approach used in clinical practice, including surgery and possible Tumor Treating Fields. |
| How it is given or performed | Patients receive oral ruxolitinib twice daily during a 6‑week chemoradiation phase then continued in 28‑day cycles, alongside daily radiation (2 Gy × 30 fractions) and temozolomide during and after radiotherapy. | Patients receive standard radiation therapy (60 Gy in 30 fractions) with concurrent then adjuvant temozolomide per standard dosing schedule. | Standard care consists of surgery when possible, followed by 6 weeks of radiation with daily temozolomide and six maintenance temozolomide cycles; Tumor Treating Fields may be used afterward. |
| Evidence status | Under evaluation in a randomized phase II trial; preliminary evidence from earlier phase I study in high‑grade glioma suggests potential activity. | Established efficacy based on randomized trials demonstrating improved survival over radiation alone (e.g., Stupp protocol). | Considered the most effective standard approach in improving survival in newly diagnosed glioblastoma. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 6 weeks of radiation plus maintenance cycles
Participants receive either ruxolitinib plus radiation and temozolomide or radiation and temozolomide alone. Radiation is given daily on weekdays for 6 weeks. Ruxolitinib and temozolomide are taken orally during radiation and continued in maintenance cycles after a break.
Weekly visits during radiation; follow-up visits during maintenance
Duration - Up to 4 years
Participants are monitored for up to 4 years to assess overall survival, tumor progression, response, and side effects. Regular evaluations and laboratory tests are conducted during this period.
Scheduled follow-up visits at regular intervals
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff...
https://pubmed.ncbi.nlm.nih.gov/24756798/Yiting Cao, Justin D Lathia, Christine E Eyler...
https://pubmed.ncbi.nlm.nih.gov/20657792/Roger Stupp, Warren P Mason, Martin J van den Bent...
https://pubmed.ncbi.nlm.nih.gov/15758009/Kimberly D Miller, Quinn T Ostrom, Carol Kruchko...
https://pubmed.ncbi.nlm.nih.gov/34427324/Olga A Guryanova, Qiulian Wu, Lin Cheng...
https://pubmed.ncbi.nlm.nih.gov/21481791/Baptist Health South Florida
Lead Sponsor
Incyte Corporation
Collaborating Sponsor